CDRD spin-off secures seed funding from Quark

Guest Contributor
April 18, 2016

Sitka Biopharma, Vancouver, has received a "significant" but unspecified seed investment from Quark Venture to advance its lead compound for treating bladder cancer into clinical trials. Sitka was spun out in 2013 from the Univ of British Columbia and the Centre for Drug Research and Development. CDRD assisted the firm in developing its nanoparticle platform technology for increasing the absorption of drugs in difficult-to-penetrate tissues, de-risking and adding value with studies to support preclinical proof-of-concept and lead candidate selection. It also helped to file patents and secure initial grants from the Canadian Institutes of Health Research and Genome British Columbia....

Other News

Events For Leaders in
Science, Tech, Innovation, and Policy

Discuss and learn from those in the know at our virtual and in-person events.

See Upcoming Events

You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in


By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.